Thermo Fisher在中国开设客户解决方案中心,以支持生物制药研发

2019-11-14 Allan MedSci原创

全球科学服务领导者,Thermo Fisher Scientific近日宣布,将在中国上海正式开设客户解决方案中心。在此之前,Thermo Fisher Scientific在上海成立了生物科学客户探索中心,并扩大了苏州的临床试验设施。新的生物制药中心将通过提供技术来支持新型高质量药物的快速交付。

全球科学服务领导者,Thermo Fisher Scientific近日宣布,将在中国上海正式开设客户解决方案中心。在此之前,Thermo Fisher Scientific在上海成立了生物科学客户探索中心,并扩大了苏州的临床试验设施。新的生物制药中心将通过提供技术来支持新型高质量药物的快速交付。

Thermo Fisher Scientific总裁Tony Acciarito表示:在中国开设制药和生物制药客户解决方案中心表明了我们坚定不移的承诺:将一流的分析技术引入该地区的实验室,通过帮助中国实验室培育创新并为等待中的患者提供有效药物


原始出处:

http://www.firstwordpharma.com/node/1680867#axzz6594Mal1B

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1988019, encodeId=8efa198801950, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sat Dec 21 19:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300329, encodeId=b6b2130032944, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387664, encodeId=9617138e664b6, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375277, encodeId=c4ef3e527708, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:35:47 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1988019, encodeId=8efa198801950, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sat Dec 21 19:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300329, encodeId=b6b2130032944, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387664, encodeId=9617138e664b6, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375277, encodeId=c4ef3e527708, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:35:47 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-16 lqvr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1988019, encodeId=8efa198801950, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sat Dec 21 19:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300329, encodeId=b6b2130032944, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387664, encodeId=9617138e664b6, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375277, encodeId=c4ef3e527708, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:35:47 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1988019, encodeId=8efa198801950, content=<a href='/topic/show?id=446a91002d6' target=_blank style='color:#2F92EE;'>#解决方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91002, encryptionId=446a91002d6, topicName=解决方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Sat Dec 21 19:07:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300329, encodeId=b6b2130032944, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387664, encodeId=9617138e664b6, content=<a href='/topic/show?id=75146922836' target=_blank style='color:#2F92EE;'>#生物制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69228, encryptionId=75146922836, topicName=生物制药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIibticIBly5jCSic5ZElW4He3rO4DMpUHUFaFX57OicNMnzckWaicBNeStwugWHFCuOdicoakApM4HGmtw/132, createdBy=f8672500006, createdName=ms6390871039024434, createdTime=Sat Nov 16 01:07:00 CST 2019, time=2019-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=375277, encodeId=c4ef3e527708, content=学习了,不错的话题,非常精彩,受益非浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7b005228115, createdName=14794e5bm67(暂无昵称), createdTime=Fri Nov 15 18:35:47 CST 2019, time=2019-11-15, status=1, ipAttribution=)]
    2019-11-15 14794e5bm67(暂无昵称)

    学习了,不错的话题,非常精彩,受益非浅

    0